Therefore, targeting H2R and its downstream coupled HCN2 channels in EPN PV neurons and H3R in STN neurons projecting to the EPN may represent potential therapeutic strategies for the clinical treatment of parkinsonism‐related motor dysfunction. This evidence concerns the gene HCN2 and Parkinson disease.